entertainment -WSS

entertainment

author：focus 2025-09-27 19:28:33 - browse：25126

Who polices algorithms? How would you name the first approved CRISPR medicine? And what pairs well with a biotech downturn?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Casey Ross joins us to tell the bombshell story of how the nation’s largest health insurer used a computer algorithm to deny patient care and boost its profitability. Then, biotech veteran Michael Gilman calls in to offer a behind-the-scenes peek at what it’s like to be a startup CEO in this economic downturn — and which cocktail recipes help make it bearable. We also discuss a pioneering approval for a genome-editing medicine.

For more on what we cover, here’s the UnitedHealth story; here’s more on the CRISPR approval; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： How to save PrEP access — and even expand it
Next article： The best solution to the drug shortages problem

explore

WSS

The best solution to the drug shortages problem

Hawaii wildfires fueled by Hurricane Dora's winds prompt evacuations

Man killed during FBI raid in connection with threats against Biden, other officials

David Liu startup to focus on CRISPR delivery

Drastic changes should bring profitability, startup health insurers say

Methadone doses haven’t kept up in the age of fentanyl

focus

entertainment

Wikipedia

Dobbs anniversary: the lost opportunity of abortion as health care

White House Covid adviser calls on docs to combat misinformation

Medical records are filled with copy

Listen: Merck v. USA, the best of ASCO, and Leqembi at the FDA

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Shkreli is convicted of fraud. Can pharma finally slam the door on him?

New air purifier tech could be key to improving indoor air quality

Methadone doses haven’t kept up in the age of fentanyl

In age of alternative facts, a scholarly course on calling out crap

What happened to the House vote on health price transparency?

entertainment

Wayne Brady comes out as pansexual: 'Free to love whomever I want'

How the messy conversation about Dolly changed bioethics

FDA weighs limits of animal data in assessing artificial wombs

In same hospitals, Black patients receive fewer opioids than white patients

Chamber of Commerce, DOJ clash in court over drug prices

Covid’s new normal has set in amid another rise in cases

hotspot

focus

explore

explore